Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Forte Biosciences, Inc.NASDAQ: FBRX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$245.51M, compared with -$169.65M a year earlier.
Context
- Retained earnings amounted to 365.2% of total assets at the end of Q1 FY2026, up 7.7 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -44.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (223.37M) USD
- Year-over-year change
- -45.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (223.37M) | -45.0% |
| FY2024 | 2024-12-31 | (154M) | -29.9% |
| FY2023 | 2023-12-31 | (118.52M) | -36.2% |
| FY2022 | 2022-12-31 | (87.04M) | -19.0% |
| FY2021 | 2021-12-31 | (73.17M) | — |
Retained Earnings vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -44.7% is the lowest of 10, against a peer median of -17.1%.
- Retained earnings amounts to 365.2% of total assets for FBRX, versus a peer median of 414.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ACTUActuate Therapeutics Inc | Mar 2026 | -$160.23M USD | -15.5% | — | 1798.1% |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$245.5M USD | -19.6% | — | 1082.0% |
| Mar 2026 | -$245.51M USD | -44.7% | — | 365.2% | |
| Mar 2026 | -CHF 323.66M CHF | -24.1% | — | 370.3% | |
| Mar 2026 | -$378.88M USD | -25.6% | — | 242.4% | |
| Mar 2026 | -$442.38M USD | -11.3% | — | 899.6% | |
| Mar 2026 | -$578.4M USD | -17.1% | — | 400.3% | |
| Mar 2026 | -$676.14M USD | -17.3% | — | 181.7% | |
| Mar 2026 | -$994.99M USD | -14.4% | — | 414.7% | |
| Mar 2026 | -$1.57B USD | -9.0% | — | 549.5% | |
| Peer median (excluding FBRX) | — | -17.1% | — | 414.7% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.